Table.
Baseline characteristics of study patients (N = 43).
| Characteristic | Nonresponders (n = 33) | Relapsers (n = 10) |
|---|---|---|
| Age, y | ||
| Mean (SD) | 44 (1) | 48 (3) |
| Range | 28–65 | 35–64 |
| Sex, no. (%) | ||
| Men | 26 (78.8) | 6 (60.0) |
| Women | 7 (21.2) | 4 (40.0) |
| Body weight, kg | ||
| Mean (SD) | 72 (1) | 72 (3) |
| Range | 63–88 | 53–115 |
| No. (%) of patients with previous IV drug abuse | 4 (12.1) | 0 (0.0) |
| No. (%) of patients with previous blood transfusion | 7 (21.2) | 3 (30.0) |
| No. (%) of patients with previous surgery | 22 (66.7) | 6 (60.0) |
| Duration of infection, y | ||
| Mean (SD) | 8.5 (1.3) | 9.6 (2.6) |
| Range | 0–29 | 1–24 |
| ALT, ×ULN | ||
| Mean (SD) | 2.84 (0.26) | 1.73 (0.20)∗ |
| Range | 1.22–8.30 | 0.50–2.92 |
| GGT, ×ULN | ||
| Mean (SD) | 1.72 (0.31) | 0.63 (0.15)† |
| Range | 0.40–8.90 | 0.10–1.82 |
| Knodell (histologic activity index) score | ||
| Mean (SD) | 8.00 (0.00) | 8.20 (1.36) |
| Range | 4–14 | 4–14 |
| Necroinflammatory activity score | ||
| Mean (SD) | 6.42 (0.66) | 6.83 (0.90) |
| Range | 3–11 | 3–11 |
| No. (%) of patients with HCV genotype 1b‡ | 14 (77.8) | 5 (83.3) |
ALT = alanine aminotransferase; ULN = upper limit of normal; GGT = gamma-glutamyl transpeptidase; HCV = hepatitis C virus.
∗
P<0.001 versus nonresponders.
†
P<0.003 versus nonresponders.
‡
Pretreatment viral genotype was assessed in 24 patients ([55.8%] 18 nonresponders and 6 relapsers).